Break it Down: GTI gets Snow Lake Energy on board
In this episode, host Tylah Tully looks at news from GTI Energy (ASX:GTR), of which its cornerstone investor - Snow Lake Energy - has been given the nod of approval to participate in a $4.5 million placement to advance Lo Herma in Wyoming.
Watch the video to learn more.
While GTI Energy is a Stockhead advertiser, it did not sponsor this content.
Originally published as Break it Down: GTI gets Snow Lake Energy on board
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
4 hours ago
- News.com.au
Comment: EV road user tax ‘makes no sense'
COMMENT: Electric car owners should pay their way, but now isn't the time to smash them with a new tax. If the government is serious about improving air quality, reducing the nation's reliance on foreign energy sources and reaching carbon emissions goals, it shouldn't discourage people from choosing electric cars. It's like tackling on the obesity problem by introducing a salad tax. It makes no sense. Hitting EV owners with an extra $500 per year – or thereabouts – in road user fees will only discourage people from going green. Yes, electric car owners do not pay the fuel excise tax that helps build and repair our roads. I reckon that's a fair price to pay, at least today, for the broader social benefits of electric cars. There are more EVs on sale than ever, and the price gap between petrol and electric cars continues to shrink. But electric cars still struggle for traction. Aussie drivers have bought 54,364 electric cars this year – just 97 more than the same period in 2024. You could hardly call that growth. Especially when sales of other vehicle types continue to grow, and electric vehicle market share has slipped from 7.4 to 7.0 per cent this year. Introducing a new pay-by-the-mile tax on electric cars would only serve to push motorists away from zero emission vehicles, back toward combustion-powered cars. And EVs need all the help they can get. Hyundai just launched the Ioniq 9, an electric cousin to the Santa Fe and Palisade. The electric model starts at about $130,000 drive-away, roughly double the asking price of its combustion-powered cousins. Kia's electric EV9 is outsold by the combustion-powered Sorento by about 30 to 1, and Volkswagen's battery-powered ID. 4 and ID. 5 duo are outsold 10 to 1 by the petrol Tiguan. Over at Toyota, deliveries of the electric bZ4X represent just 0.3 per cent of its 142,700 sales this year. EVs are here. Customers just aren't choosing them. There are headlines just about every day from car companies trying to figure out how to handle EVs in Australia. Hyundai says it has done 'a terrible job' convincing customers to make the switch, Honda says there is 'a lot of noise' surrounding EVs while people quietly buy hybrids and Suzuki, plainly, says they 'just don't think the Australian market wants them'. They might be right. We quizzed more than 50,000 readers earlier this year as part of The Great Aussie Debate and found that only 14.9 per cent of people were considering an EV for their next car. That represented a drop from 18.9 per cent in 2023. The government wants us to get behind the wheel of electric cars, even if we don't want to choose them. A new tax is a strange way to try and change that.
The Australian
5 hours ago
- The Australian
Leading ED specialist joins LTR Pharma's US advisory
Leading US erectile dysfunction specialist Dr Amy Pearlman to join LTR Pharma scientific advisory board Appointment supports launch of ROXUS in H1 CY26 with Pearlman to advise on medical education and prescriber engagement strategies Special Report: LTR Pharma has announced a key appointment to its scientific advisory board as it gears up to launch its innovative nasal spray-mist to treat erectile dysfunction (ED) products in the US. Strengthens US market entry capabilities for Roxus and SPONTAN, targeting the US$3.7 billion erectile dysfunction market US board-certified urologist and nationally recognised leader in sexual medicine Dr Amy Pearlman has joined the LTR Pharma (ASX:LTP) scientific advisory board. As a member of the board Pearlman will provide strategic clinical insight, medical engagement, and market access strategies for SPONTAN and ROXUS, the company's nasal spray treatments for ED. Pearlman is co-founder of Prime Institute in Coral Gables, Florida, which is a premium private medical practice focused on optimising cardiometabolic, hormonal, and sexual health in men and women. She is a former director of the Men's Health Program at the University of Iowa and a fellowship-trained specialist in male sexual and hormonal health. Pearlman has trained at leading US medical institutions and built a distinguished career in sexual medicine, serving on boards and editorial panels for major professional bodies including the Sexual Medicine Society of North America and Urology Times. An active member of the American Urological Association, she specialises in both medical and surgical management of a range of sexual health conditions for both men and women. As a prominent voice in sexual health innovation LTR Pharma said Pearlman bought extensive expertise in ED treatment, testosterone optimisation, and comprehensive approaches to sexual wellness. She has contributed to the Fifth International Consultation on Sexual Medicine (ICSM 2024), shaping global policy and recommendations in sexual health alongside leading international experts. Bolstering clinical expertise for US push Pearlman's appointment significantly enhances LTR Pharma's clinical expertise as it prepares for expansion into the US market with a deep understanding of the American healthcare landscape. The company said her established relationships with key opinion leaders, and a proven record in advancing innovative treatments would be instrumental in positioning SPONTAN and Roxus for success in North America. Pearlman is set to play a pivotal role in building prescriber awareness for the company's rapid-onset ED treatments. Her thought leadership is widely recognised through national media appearances, conference presentations, and her popular podcast Pearls and Perspectives. Pearlman has been honoured with international professorships and is frequently invited as a keynote speaker at major urological and sexual medicine conferences globally. 'Compelling alternative' to current treatments Pearlman said she believed SPONTAN and ROXUS would be important additions to treatment options in the US for men seeking effective, rapid-onset ED treatment. 'The intranasal delivery platform offers a compelling alternative to current oral medications, providing onset of action in 10 minutes or less with an excellent safety profile,' she said. 'Having dedicated my career to advancing sexual health and wellness, I'm thrilled to join LTR Pharma's scientific advisory board and contribute to bringing these innovative treatments to American patients who deserve better options for spontaneous intimacy." LTR Pharma executive chairman Lee Rodne said the company was honoured to welcome Pearlman to its scientific advisory board. 'Her recognised expertise in sexual medicine, combined with her innovative approach to patient care and treatment, makes her an invaluable addition to our team. Rodne said Pearlman's appointment is a critical milestone in the company's US market entry strategy, with ROXUS planned for launch in H1 CY26. 'Her relationships with prescribers and her influential position within the American urological and sexual health community will be crucial as we build momentum in the world's largest pharmaceutical market,' he said. 'Her appointment underscores our commitment to assembling world-class expertise to deliver innovative treatments for erectile dysfunction." This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
The Australian
6 hours ago
- The Australian
StockTake: Belararox
Stockhead's Tylah Tully looks at news from Belararox (ASX:BRX), who is gearing up to drill in Botswana. The company is planning 3,000 metres of RC drilling at the Kalahari copper project later this month, targeting 3 of 5 key target zones at the Kareng West licence. Watch the video to learn more. This video was developed in collaboration with Belararox, a Stockhead advertiser at the time of publishing. This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
